Extended Data Fig. 4: Efficient tumour rejection by anti-PD-L1 and anti-TIGIT mAbs treatment depends on functional Fc-FcɣR interaction axis.
From: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
![Extended Data Fig. 4](https://cdn.statically.io/img/media.springernature.com/full/springer-static/esm/art%3A10.1038%2Fs41586-024-07121-9/MediaObjects/41586_2024_7121_Fig10_ESM.jpg)
a, Plots depicting tumour volumes in each mouse over time; data are representative of one independent experiment. Wildtype BALB/c mice were implanted with CT26 tumours and then treated as described in the method. b, Plots depicting tumour volumes in each mouse over time; data are representative of one independent experiment. Wildtype (top) and FcɣR knockout (bottom) BALB/c mice were implanted with CT26 tumours and then treated as described in the method.